B. Metzler seel. Sohn & Co. Holding AG bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,360 shares of the biopharmaceutical company's stock, valued at approximately $3,532,000.
Several other large investors also recently modified their holdings of the stock. Quent Capital LLC raised its holdings in shares of Regeneron Pharmaceuticals by 5.1% during the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company's stock valued at $375,000 after purchasing an additional 19 shares during the period. Bessemer Group Inc. raised its stake in Regeneron Pharmaceuticals by 107.1% during the 1st quarter. Bessemer Group Inc. now owns 5,075 shares of the biopharmaceutical company's stock worth $4,886,000 after buying an additional 2,624 shares during the period. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $28,000. CreativeOne Wealth LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $200,000. Finally, Freestone Capital Holdings LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $570,000. Institutional investors and hedge funds own 83.31% of the company's stock.
In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm's stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.48% of the stock is currently owned by corporate insiders.
REGN has been the topic of several recent research reports. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, October 22nd. Leerink Partnrs lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $1,099.55.
View Our Latest Stock Report on Regeneron Pharmaceuticals
NASDAQ REGN opened at $743.35 on Thursday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market cap of $81.69 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 2.86 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $736.01 and a 52 week high of $1,211.20. The firm's 50-day simple moving average is $961.76 and its two-hundred day simple moving average is $1,030.14.
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.